356 related articles for article (PubMed ID: 8165649)
1. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
Meyer G; Brenot F; Pacouret G; Simonneau G; Gillet Juvin K; Charbonnier B; Sors H
Thromb Haemost; 1995 Dec; 74(6):1432-5. PubMed ID: 8772215
[TBL] [Abstract][Full Text] [Related]
4. Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapy.
Monreal M
Semin Thromb Hemost; 1997; 23(1):69-75. PubMed ID: 9156413
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
[TBL] [Abstract][Full Text] [Related]
6. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term therapy with either heparin or low-molecular-weight heparin on serum lipid levels. A prospective study.
Monreal M; Lafoz E; Urrutia A; Roncales J; Galimany R; Biosca C; Corominas A
Haemostasis; 1995; 25(6):283-7. PubMed ID: 8586319
[TBL] [Abstract][Full Text] [Related]
8. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
10. Outpatient treatment of pulmonary embolism with dalteparin.
Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
[TBL] [Abstract][Full Text] [Related]
11. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Prandoni P; Carnovali M; Marchiori A;
Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
[TBL] [Abstract][Full Text] [Related]
13. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
14. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
15. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.
Alhenc-Gelas M; Jestin-Le Guernic C; Vitoux JF; Kher A; Aiach M; Fiessinger JN
Thromb Haemost; 1994 Jun; 71(6):698-702. PubMed ID: 7974334
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
Prandoni P; Simioni P; Pagnan A
Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
[TBL] [Abstract][Full Text] [Related]
17. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443
[TBL] [Abstract][Full Text] [Related]
20. [-Anticoagulant drugs-].
Gulba DC
Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
